CureVac BV (CVAC) Stock Price Today
Key Stats
- $1.05BMARKET_CAP
- -VOLUME
- HealthSECTOR
- $5.60FIFTY_TWO_WEEK_HIGH
- $2.59FIFTY_TWO_WEEK_LOW
- -TYPICAL_HOLD_TIME
- $599.28MENTERPRISE_VALUE
- -DIVIDEND_YIELD
- -TRADING_ACTIVITY
Track CureVac BV (CVAC) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, CureVac BV has traded between a low of $2.59 and a high of $5.6, highlighting its annual price range. Buy and sell CureVac BV shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About CureVac BV
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.
Most Recent News
Taiwan Freedom Project launches to defend Taiwan's sovereignty and counter CCP influence through information.
The Taiwan Freedom Project has launched a special publication in The Washington Times to highlight Taiwan's geopolitical importance and counter Chinese Communist Party (CCP) narratives. The 32-page section features bipartisan U.S. lawmakers and Taiwa...
Michael and Susan Dell pledge $6B to fund 'Trump Accounts' for young Americans' financial future
Michael and Susan Dell have pledged over $6 billion to support 'Trump Accounts,' a new public-private initiative launched on July 4 that gives millions of young Americans a financial stake in the economy. Eligible children born between 2025 and 2028 ...
Core Scientific shifts to AI colocation with $77.5M Q1 2026 revenue and strong profit margins amid supply constraints.
Core Scientific is transitioning from Bitcoin mining to becoming a high-density AI colocation provider, reporting $77.5 million in colocation revenue for Q1 2026 with a 57% gross profit margin. This shift is supported by a multi-gigawatt power pipeli...
